NasdaqGS - Nasdaq Real Time Price USD

Aardvark Therapeutics, Inc. Common Stock (AARD)

7.85

+0.23

+(3.02%)

As of 9:30:40 AM EDT. Market Open.

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16-point HQ-CT reduction, with an average reduction of approximately 8 points among subjects that followed trial protocol) observed during the 28-day dosing period. DEXA scans analysis from the PWS Phase 2 trial data measuring body composition indicated a trend toward decreased body fat (approximately

GlobeNewswire 14 days ago

AARD
+3.02%
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed.

Investor's Business Daily 18 days ago

AARD
+3.02%
SLNO
Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the U.S. economy? What’s next on President […]

Insider Monkey last month

AARD
+3.02%
Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are going to take a look at where Aardvark Therapeutics, Inc. (NASDAQ:AARD) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump took office, the stock market has […]

Insider Monkey last month

AARD
+3.02%
Aardvark Therapeutics Announces Pricing of Initial Public Offering

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the pricing of its initial public offering of 5,888,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Aardvark. The gross proceeds to

GlobeNewswire last month

AARD
+3.02%

Performance Overview

Return	AARD	S&P 500 (^GSPC)
YTD	-48.29%	-7.61%
1-Year	-48.29%	+7.35%
3-Year	-48.29%	+23.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aardvark Therapeutics, Inc. Common Stock (AARD)

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month

Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently

Aardvark Therapeutics Announces Pricing of Initial Public Offering

Performance Overview